stockrowThermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.
- Revenue
- +9.13%
- EPS
- +8.64%
- Free cash flow
- +15.0%
- Total debt
- +22.8%
Quarter to September 2026, against a year earlier
Follow TMO
Alert me
Thermo Fisher Scientific Inc. (TMO) Net income
Thermo Fisher Scientific Inc.'s net income for fiscal 2025 was $6.7B, up 6.04% from $6.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $7.1B. Over the past ten years it has ranged from $2.0B (fiscal 2015) to $7.7B (fiscal 2021); the current reading is higher than 82% of that period. Thermo Fisher Scientific Inc. ranks 1st of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $6.7B | 6.04% |
| FY2024 | $6.3B | 6.43% |
| FY2023 | $6.0B | (14.44%) |
| FY2022 | $7.0B | (9.94%) |
| FY2021 | $7.7B | 21.19% |
| FY2020 | $6.4B | 72.44% |
| FY2019 | $3.7B | 25.87% |
| FY2018 | $2.9B | 32.04% |
| FY2017 | $2.2B | 10.04% |
| FY2016 | $2.0B | 2.38% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $1.7B | (0.80%) |
| Jun 2026 | $1.7B | 5.13% |
| Mar 2026 | $1.7B | (15.94%) |
| Dec 2025 | $2.0B | 21.53% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TMO Thermo Fisher Scientific Inc. | $7.1B |
| DHR Danaher Corporation compare | $4.3B |
| A Agilent Technologies, Inc. compare | $1.4B |
| IQV IQVIA Holdings Inc. compare | $1.4B |
| IDXX IDEXX Laboratories, Inc. compare | $1.2B |
| MTD Mettler-Toledo International, Inc. compare | $905.6M |
| ILMN Illumina, Inc. compare | $895.0M |
| WAT Waters Corporation compare | $98.2M |
| NTRA Natera, Inc. compare | −$164.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TMO
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement